Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2010

View Archived Issues

GlaxoSmithKline presents new calcium receptor antagonists

Pfizer describes novel AMPA receptor agonists

Humoral responses to DC-Melvac cancer vaccine seen in melanoma patients

Hepatitis C treatment SCY-635 associated with a high barrier to resistance

INT-747 promising as add-on therapy to ursodeoxycholic acid for primary biliary cirrhosis

Updated phase I data disclosed on IMO-2125 in HCV infection

EMD-1214063 displays potent and selective c-Met inhibition

Telik presents novel Aurora A/B and VEGFR-2 inhibitors

Dual TLR7 and TLR9 antagonist has therapeutic effects in mouse model of atherosclerosis

New FAAH inhibitors claimed by Renovis

Novartis reports R&D highlights for first quarter of 2010

Temozolomide shows activity in pituitary tumors and carcinomas

Oncolytics Biotech completes phase I enrollment for phase I/II Reolysin trial

FDA recommends reformulation of UCB's Neupro

Nycomed and Merck & Co. collaborate on commercialization of roflumilast in Canada and Europe

EMA's CHMP recommends extending indication of tocilizumab

ALK to acquire Fornix Biosciences' allergy division in The Netherlands

Penwest provides update on focused business plan

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

New FDA initiative to reduce risks related to infusion pumps

Presidio and Numerate end HCV research collaboration

Michael J. Fox Foundation awards grants to advance Parkinson's disease research

Stem Cell Therapeutics completes 90-day endpoint period for REGENESIS trial

ACT completes studies to support phase I stem cell trial in SMD

AD-02 Alzheimer's vaccine progresses to phase II

CHMP recommends conditional marketing approval for Votrient

Proteo completes patient recruitment in phase II Elafin trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...